Universe Pharmaceuticals (UPC) Receivables Refunds (2023 - 2025)
Universe Pharmaceuticals' Receivables Refunds history spans 3 years, with the latest figure at $1.0 billion for Q3 2025.
- For Q3 2025, Receivables Refunds rose 115.24% year-over-year to $1.0 billion; the TTM value through Sep 2025 reached $1.0 billion, up 115.24%, while the annual FY2025 figure was $1.0 billion, 115.24% up from the prior year.
- Receivables Refunds for Q3 2025 was $1.0 billion at Universe Pharmaceuticals, up from $475.3 million in the prior quarter.
- Across five years, Receivables Refunds topped out at $1.0 billion in Q3 2025 and bottomed at $478899.0 in Q3 2023.
- The 3-year median for Receivables Refunds is $475.3 million (2024), against an average of $499.6 million.
- The largest annual shift saw Receivables Refunds surged 99154.96% in 2024 before it soared 115.24% in 2025.
- A 3-year view of Receivables Refunds shows it stood at $478899.0 in 2023, then soared by 99154.96% to $475.3 million in 2024, then soared by 115.24% to $1.0 billion in 2025.
- Per Business Quant, the three most recent readings for UPC's Receivables Refunds are $1.0 billion (Q3 2025), $475.3 million (Q3 2024), and $478899.0 (Q3 2023).